NASDAQ:GLPG - Galapagos Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $154.58
  • Forecasted Upside: 91.62 %
  • Number of Analysts: 17
  • Breakdown:
  • 2 Sell Ratings
  • 11 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$80.67
▼ -3.03 (-3.62%)
1 month | 3 months | 12 months
Get New Galapagos Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GLPG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GLPG

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$154.58
▲ +91.62% Upside Potential
This price target is based on 17 analysts offering 12 month price targets for Galapagos in the last 3 months. The average price target is $154.58, with a high forecast of $290.00 and a low forecast of $94.00. The average price target represents a 91.62% upside from the last price of $80.67.
Hold
The current consensus among 17 polled investment analysts is to hold stock in Galapagos. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
9/15/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 8 hold ratings
  • 0 sell ratings
12/14/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 10 hold ratings
  • 0 sell ratings
3/13/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 11 hold ratings
  • 0 sell ratings
6/11/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 11 hold ratings
  • 0 sell ratings
9/9/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 12 hold ratings
  • 1 sell ratings
12/8/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 11 hold ratings
  • 2 sell ratings
2/6/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 11 hold ratings
  • 2 sell ratings
3/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 11 hold ratings
  • 2 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/2/2021BarclaysReiterated RatingEqual WeightLow
i
2/25/2021Raymond JamesUpgradeMarket Perform ➝ Outperform$100.00Low
i
2/23/2021Bank of AmericaUpgradeUnderperform ➝ Neutral$93.00 ➝ $94.00Low
i
2/19/2021Raymond JamesUpgradeMarket Perform ➝ OutperformLow
i
2/11/2021UBS GroupReiterated RatingNeutralLow
i
2/11/2021CitigroupDowngradeBuy ➝ NeutralLow
i
2/10/2021Maxim GroupDowngradeBuy ➝ HoldLow
i
1/19/2021BarclaysBoost Price TargetEqual Weight$85.50 ➝ $125.00Low
i
1/19/2021Morgan StanleyUpgradeEqual Weight ➝ OverweightMedium
i
12/17/2020Maxim GroupLower Price Target$140.00 ➝ $170.00High
i
12/17/2020Smith Barney CitigroupReiterated RatingBuyHigh
i
12/17/2020Bryan, Garnier & CoDowngradeBuy ➝ SellHigh
i
11/23/2020UBS GroupReiterated RatingNeutralLow
i
11/19/2020Maxim GroupInitiated CoverageBuy$170.00Low
i
11/12/2020JPMorgan Chase & Co.Lower Price TargetNeutral$152.00 ➝ $142.00Medium
i
10/21/2020The Goldman Sachs GroupDowngradeNeutral ➝ SellLow
i
10/16/2020UBS GroupReiterated RatingNeutralLow
i
10/16/2020Royal Bank of CanadaLower Price TargetSector Perform$135.00 ➝ $131.00High
i
10/13/2020BarclaysReiterated RatingEqual WeightLow
i
10/13/2020Morgan StanleyBoost Price TargetEqual Weight$158.00 ➝ $159.00Low
i
10/8/2020UBS GroupReiterated RatingNeutralLow
i
9/25/2020Stifel NicolausReiterated RatingHoldLow
i
Rating by Derek Archila at Stifel Nicolaus
9/24/2020JPMorgan Chase & Co.Reiterated RatingNeutralMedium
i
9/11/2020Stifel NicolausReiterated RatingHoldLow
i
Rating by Derek Archila at Stifel Nicolaus
8/25/2020Jefferies Financial GroupDowngradeBuy ➝ HoldLow
i
Rating by Peter Welford at Jefferies Financial Group Inc.
8/24/2020HC WainwrightDowngradeBuy ➝ Neutral$270.00 ➝ $123.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
8/21/2020Morgan StanleyLower Price TargetEqual Weight$221.00 ➝ $158.00Low
i
8/21/2020Bank of AmericaLower Price TargetUnderperform$148.00 ➝ $134.00Low
i
8/19/2020CitigroupUpgradeNeutral ➝ BuyHigh
i
8/19/2020Cantor FitzgeraldLower Price TargetNeutral$192.00 ➝ $134.00High
i
Rating by E. Merle at Cantor Fitzgerald
8/19/2020BarclaysDowngradeOverweight ➝ Equal WeightHigh
i
8/18/2020Stifel NicolausReiterated RatingHold$155.00High
i
Rating by Derek Archila at Stifel Nicolaus
8/11/2020BarclaysReiterated RatingOverweightMedium
i
8/10/2020Morgan StanleyLower Price TargetEqual Weight$224.00 ➝ $221.00Low
i
8/7/2020Stifel NicolausReiterated RatingHold$187.00High
i
Rating by Derek Archila at Stifel Nicolaus
7/24/2020HC WainwrightReiterated RatingBuy$270.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
7/15/2020Morgan StanleyLower Price TargetEqual Weight$226.00 ➝ $224.00Low
i
7/10/2020Stifel NicolausDowngradeBuy ➝ Hold$298.00 ➝ $193.00High
i
Rating by Adam Walsh at Stifel Nicolaus
5/21/2020NomuraReiterated RatingBuy$290.00Medium
i
5/21/2020HC WainwrightLower Price TargetBuy$302.00 ➝ $270.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
5/18/2020UBS GroupReiterated RatingNeutralMedium
i
Rating by Laura Sutcliffe at UBS Group AG
5/15/2020BarclaysReiterated RatingOverweightLow
i
4/15/2020Morgan StanleyBoost Price TargetEqual Weight$220.00 ➝ $226.00Low
i
Rating by Matthew Harrison at Morgan Stanley
4/13/2020Royal Bank of CanadaReiterated RatingHold$155.00Low
i
3/30/2020Jefferies Financial GroupUpgradeHold ➝ Buy$232.00Low
i
3/18/2020Royal Bank of CanadaUpgradeUnderperform ➝ Sector Perform$175.00 ➝ $157.00Low
i
3/2/2020JPMorgan Chase & Co.Lower Price TargetNeutral$205.00 ➝ $200.00High
i
Rating by James Quigley at JPMorgan Chase & Co.
2/26/2020Morgan StanleyBoost Price TargetEqual Weight$215.00 ➝ $220.00Low
i
Rating by Matthew Harrison at Morgan Stanley
2/26/2020Nomura SecuritiesReiterated RatingBuy$209.00 ➝ $290.00Low
i
2/25/2020Cantor FitzgeraldDowngradeOverweight ➝ Neutral$187.00 ➝ $192.00High
i
Rating by E. Merle at Cantor Fitzgerald
2/24/2020HC WainwrightReiterated RatingBuy$205.00 ➝ $302.00High
i
2/24/2020CitigroupDowngradeNeutral ➝ Underperform$213.00High
i
Rating by Nick Nieland at Citigroup Inc.
2/24/2020Stifel NicolausReiterated RatingBuy$188.00 ➝ $298.00High
i
2/24/2020Bank of AmericaDowngradeNeutral ➝ Underperform$213.00High
i
Rating by Jason Gerberry at Bank of America Co.
2/20/2020Royal Bank of CanadaDowngradeSector Perform ➝ Underperform$175.00High
i
1/5/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$205.00N/A
i
12/20/2019UBS GroupDowngradeBuy ➝ NeutralLow
i
12/18/2019CitigroupDowngradeBuy ➝ NeutralLow
i
12/17/2019Morgan StanleyDowngradeOverweight ➝ Equal$193.00 ➝ $215.00Low
i
12/13/2019Credit Suisse GroupDowngradeOutperform ➝ Neutral$174.00 ➝ $169.00Medium
i
12/2/2019Bank of AmericaInitiated CoverageNeutral$199.00Low
i
11/15/2019Royal Bank of CanadaBoost Price TargetSector Perform$152.00 ➝ $158.00Low
i
10/29/2019Morgan StanleyLower Price TargetOverweight$193.00Low
i
9/9/2019Morgan StanleyInitiated CoverageOverweight$200.00Medium
i
7/31/2019UBS GroupUpgradeNeutral ➝ BuyLow
i
7/29/2019Nomura SecuritiesBoost Price TargetBuy$140.00 ➝ $209.00Medium
i
7/29/2019Royal Bank of CanadaBoost Price Target$171.00Low
i
7/29/2019Jefferies Financial GroupDowngradeBuy ➝ HoldLow
i
7/26/2019CowenReiterated RatingBuyLow
i
7/15/2019Raymond JamesDowngradeStrong-Buy ➝ Market PerformLow
i
7/15/2019Stifel NicolausBoost Price TargetBuy$121.00 ➝ $188.00High
i
7/15/2019HC WainwrightBoost Price TargetBuy ➝ Buy$150.00 ➝ $205.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
7/10/2019Credit Suisse GroupReiterated RatingOutperformLow
i
7/2/2019HC WainwrightSet Price TargetBuy$150.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
6/12/2019HC WainwrightReiterated RatingBuy$150.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
5/23/2019HC WainwrightSet Price TargetBuy$150.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
5/2/2019Cantor FitzgeraldReiterated RatingBuy$130.00Low
i
Rating by Eliana Merle at Cantor Fitzgerald
4/29/2019Morgan StanleyBoost Price TargetOverweight ➝ Overweight$138.00 ➝ $139.00Low
i
4/26/2019Cantor FitzgeraldSet Price TargetBuy$130.00Low
i
Rating by Eliana Merle at Cantor Fitzgerald
3/29/2019HC WainwrightBoost Price TargetPositive$150.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
3/28/2019HC WainwrightInitiated CoverageBuy ➝ Buy$136.00 ➝ $136.00Low
i
Rating by D. Chattopadhyay at HC Wainwright
3/26/2019Cantor FitzgeraldSet Price TargetBuy$130.00Medium
i
Rating by Eliana Merle at Cantor Fitzgerald
2/22/2019CowenReiterated RatingBuyLow
i
2/22/2019SVB LeerinkInitiated CoverageOutperform$140.00Low
i
12/19/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$130.00Medium
i
12/13/2018Credit Suisse GroupUpgradeNeutral ➝ OutperformHigh
i
Rating by Vamil Divan at Credit Suisse Group AG
11/14/2018Raymond JamesInitiated CoverageStrong-Buy ➝ Strong-Buy$157.00Low
i
11/5/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$127.00 ➝ $131.00Low
i
10/30/2018Nomura SecuritiesBoost Price TargetBuy ➝ Buy$124.00 ➝ $140.00Low
i
10/26/2018Credit Suisse GroupLower Price TargetNeutral ➝ Hold$92.00 ➝ $90.00Low
i
Rating by Vamil Divan at Credit Suisse Group AG
9/12/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$140.00High
i
9/12/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$109.00 ➝ $111.00High
i
8/17/2018The Goldman Sachs GroupReiterated RatingNeutralLow
i
Rating by Keyur Parekh at The Goldman Sachs Group, Inc.
8/9/2018The Goldman Sachs GroupDowngradeBuy ➝ NeutralMedium
i
Rating by Keyur Parekh at The Goldman Sachs Group, Inc.
8/7/2018Credit Suisse GroupSet Price TargetNeutral ➝ Hold$85.00 ➝ $92.00Low
i
Rating by Vamil Divan at Credit Suisse Group AG
8/6/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$126.00 ➝ $127.00Low
i
7/13/2018Morgan StanleyBoost Price TargetOverweight$125.00 ➝ $126.00Low
i
6/29/2018Royal Bank of CanadaLower Price TargetSector Perform$94.00High
i
6/29/2018Stifel NicolausLower Price TargetBuy ➝ Buy$120.00 ➝ $109.00High
i
5/31/2018CowenReiterated RatingBuyLow
i
4/29/2018BTIG ResearchReiterated RatingBuy$118.00Low
i
2/8/2018BTIG ResearchReiterated RatingBuy$118.00High
i
11/20/2017BTIG ResearchReiterated RatingBuy$118.00N/A
i
10/29/2017Stifel NicolausReiterated RatingBuy$120.00N/A
i
Rating by Adam Walsh at Stifel Nicolaus
10/6/2017Morgan StanleyReiterated RatingOverweight$92.00 ➝ $123.00N/A
i
9/15/2017Stifel NicolausBoost Price TargetBuy ➝ Buy$101.00 ➝ $120.00Low
i
Rating by Adam Walsh at Stifel Nicolaus
9/14/2017Royal Bank of CanadaInitiated CoverageSector Perform$98.00Medium
i
8/11/2017Nomura SecuritiesBoost Price TargetBuy$108.00 ➝ $124.00Low
i
8/11/2017Stifel NicolausUpgradeHold ➝ Buy$83.00 ➝ $101.00Medium
i
Rating by Adam Walsh at Stifel Nicolaus
8/10/2017Morgan StanleyReiterated RatingOverweight$92.00Medium
i
8/10/2017CowenReiterated RatingBuyMedium
i
7/26/2017BTIG ResearchReiterated RatingBuy$98.00Medium
i
7/20/2017BTIG ResearchReiterated RatingBuy$98.00High
i
7/7/2017Janney Montgomery ScottUpgradeSell ➝ NeutralLow
i
Rating by Debjit Chattopadhyay at Janney Montgomery Scott
6/22/2017Nomura InstinetReiterated RatingBuy$121.00 ➝ $108.00Low
i
6/22/2017Nomura SecuritiesLower Price TargetBuy$108.00 ➝ $121.00Low
i
6/21/2017CowenReiterated RatingBuyLow
i
Rating by Phil Nadeau at Cowen Inc
6/20/2017BTIG ResearchReiterated RatingBuy$98.00High
i
5/1/2017Stifel NicolausBoost Price TargetHold$65.00 ➝ $83.00Low
i
Rating by Adam Walsh at Stifel Nicolaus
4/24/2017Janney Montgomery ScottDowngradeBuy ➝ SellHigh
i
3/1/2017Nomura InstinetInitiated CoverageBuy ➝ Buy$87.00N/A
i
3/1/2017Nomura SecuritiesInitiated CoverageBuyN/A
i
1/5/2017Stifel NicolausInitiated CoverageHold$65.00N/A
i
12/23/2016CowenReiterated RatingBuyN/A
i
Rating by Phil Nadeau at Cowen Inc
10/30/2016CowenReiterated RatingBuyN/A
i
Rating by Phil Nadeau at Cowen Inc
10/18/2016The Goldman Sachs GroupUpgradeNeutral ➝ BuyN/A
i
8/30/2016Janney Montgomery ScottInitiated CoverageBuy ➝ Buy$64.00N/A
i
6/17/2016Credit Suisse GroupReiterated RatingHold$48.00N/A
i
5/2/2016Morgan StanleyReiterated RatingBuy$89.00N/A
i
5/2/2016Morgan StanleyLower Price TargetOverweight$92.00 ➝ $89.00N/A
i
4/30/2016CowenReiterated RatingBuyN/A
i
Rating by Phil Nadeau at Cowen Inc
4/8/2016Morgan StanleyBoost Price Target$89.00 ➝ $92.00N/A
i
(Data available from 3/9/2016 forward)
Galapagos logo
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjögren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.
Read More

Today's Range

Now: $80.67
$80.63
$82.36

50 Day Range

MA: $95.48
$82.32
$111.94

52 Week Range

Now: $80.67
$80.63
$233.14

Volume

286,806 shs

Average Volume

330,804 shs

Market Capitalization

$5.28 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.76

Frequently Asked Questions

What sell-side analysts currently cover shares of Galapagos?

The following sell-side analysts have issued stock ratings on Galapagos in the last twelve months: Bank of America Co., Barclays PLC, Bryan, Garnier & Co, Cantor Fitzgerald, Citigroup Inc., HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Maxim Group, Morgan Stanley, Nomura, Raymond James, Royal Bank of Canada, Smith Barney Citigroup, Stifel Nicolaus, The Goldman Sachs Group, Inc., TheStreet, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for GLPG.

What is the current price target for Galapagos?

12 Wall Street analysts have set twelve-month price targets for Galapagos in the last year. Their average twelve-month price target is $154.58, suggesting a possible upside of 88.2%. Nomura has the highest price target set, predicting GLPG will reach $290.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $94.00 for Galapagos in the next year.
View the latest price targets for GLPG.

What is the current consensus analyst rating for Galapagos?

Galapagos currently has 2 sell ratings, 11 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GLPG, but not buy more shares or sell existing shares.
View the latest ratings for GLPG.

What other companies compete with Galapagos?

How do I contact Galapagos' investor relations team?

Galapagos' physical mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The biotechnology company's listed phone number is 321-534-2900 and its investor relations email address is [email protected] The official website for Galapagos is www.glpg.com.